Welcome to the Oncology Brothers podcast! In this episode, we welcomed Dr. Neil Iyengar and Dr. Emily Gallagher, to dive deep into the world of PIK3CA and AKT pathway inhibitors for hormone receptor-positive (HR+) metastatic breast cancer.

We discussed the latest approvals, including Inavolisib, Alpelisib, and Capivasertib, and explored their common side effects such as hyperglycemia, rash, and gastrointestinal issues. Our experts shared practical management strategies, dosing considerations, and the importance of patient education to ensure safe and effective treatment.

Key topics covered in this episode:

• Overview of PIK3CA and AKT inhibitors
• Common side effects and their management
• The significance of proactive patient education
• Dosing strategies and when to consider dose modifications
• Insights on managing hyperglycemia and gastrointestinal symptoms

This episode is packed with valuable information to enhance your understanding of these important therapies in the breast cancer world.

Listen us on:
Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o

Follow us on social media:

• ⁠X/Twitter: https://twitter.com/oncbrothers
• Instagram: https://www.instagram.com/oncbrothers
• Website: https://oncbrothers.com/

Don't forget to subscribe for more episodes on treatment algorithms, toxicities, and the latest in oncology!

PI3Kinhibitors #BreastCancer #Hyperglycemia #ToxCheck #MetastaticBC #OncologyBrothers #TargetedTherapy